Leuphasyl (Pentapeptide-18 / Acetyl Glutamyl Heptapeptide-1): Complete Research Profile — Enkephalin Pathway Modulation and Neuropeptide Wrinkle Research (2026)

# Leuphasyl (Pentapeptide-18 / Acetyl Glutamyl Heptapeptide-1): Complete Research Profile — Enkephalin Pathway Modulation and Neuropeptide Wrinkle Research (2026)

> For research purposes only. Not for human use.

Leuphasyl — classified by INCI nomenclature as Acetyl Glutamyl Heptapeptide-1 and frequently cited in the research literature as Pentapeptide-18 — is a synthetic cosmeceutical neuropeptide developed by Lipotec S.A. (now Lubrizol Life Science) that models its mechanism of action on enkephalins, the endogenous opioid neuropeptides responsible for modulating neuromuscular transmission and pain signal propagation. Unlike Argireline (Acetyl Hexapeptide-8), which targets the SNARE presynaptic exocytosis complex, Leuphasyl operates upstream at the opioid receptor level on nerve cell membranes, reducing calcium-dependent catecholamine release and thereby producing a complementary inhibition of the neuromuscular signaling cascade underlying facial expression wrinkle formation.

This research profile covers Leuphasyl's molecular identity, enkephalin receptor pharmacology, neuromuscular modulation mechanism, clinical efficacy data, synergistic behavior with complementary cosmetic peptides, and its position within the broader landscape of cosmeceutical neuropeptide research — presented strictly for Research Use Only (RUO) purposes.

---

Molecular Identity and Structure

Leuphasyl's peptide sequence is derived from Leu-enkephalin (Tyr-Gly-Gly-Phe-Leu), one of the two primary endogenous opioid pentapeptides produced by the brain, spinal cord, and peripheral nervous system. The synthetic Leuphasyl sequence preserves the core enkephalin pharmacophore while incorporating stabilizing modifications — including N-terminal acetylation — that improve metabolic resistance to peptidase degradation relative to the native enkephalin sequence.

The acetyl group at the N-terminus is critical: unmodified enkephalin is rapidly cleaved by aminopeptidases and enkephalinase (neutral endopeptidase, neprilysin) in both plasma and skin tissue. N-acetylation substantially reduces this enzymatic degradation, extending the functional half-life of the compound in the skin microenvironment relevant to topical applications.

---

The Enkephalin Pathway in Neuromuscular Biology

Endogenous Enkephalins: Neuromodulatory Context

Enkephalins are endogenous opioid pentapeptides that serve as natural neuromodulators at synaptic junctions throughout the peripheral and central nervous system. They act as retrograde signaling molecules, released from postsynaptic cells and binding to presynaptic delta (δ) and mu (μ) opioid receptors expressed on motor nerve terminals and sensory neurons. This receptor engagement activates inhibitory G-proteins (Gi/Go), which:

1. Inhibit adenylyl cyclase, reducing cAMP-dependent neurotransmitter release

2. Block voltage-gated calcium channels (N-type and P/Q-type), reducing Ca²⁺ influx into the presynaptic terminal

3. Activate inwardly rectifying potassium channels, hyperpolarizing the nerve terminal and reducing action potential firing probability

The net effect of enkephalin receptor activation is a reduction in calcium-dependent exocytosis of neurotransmitter-containing vesicles — including both acetylcholine (ACh) at the NMJ and catecholamine neurotransmitters at adrenergic synapses. This positions enkephalins as key modulators of the neuromuscular excitability that drives repetitive facial muscle contraction and the expression lines that form over time.

Age-Related Decline in Enkephalin Tone

Research in neuroendocrinology has documented age-dependent changes in central and peripheral opioid system activity, with some evidence suggesting reduced enkephalinergic tone in aging tissue. This decline in endogenous neuromodulatory capacity at the NMJ level may contribute to increased baseline muscle contractile tone and altered synaptic dynamics in aging facial musculature — a context in which a biomimetic enkephalin analog would have a theoretically meaningful research application.

---

Mechanism of Action: Opioid Receptor Agonism at the Dermal NMJ

Receptor-Level Inhibition

Leuphasyl's functional mechanism begins with binding to opioid receptors on the surface of motor nerve terminals innervating facial mimetic muscles. The compound's enkephalin-derived sequence confers sufficient receptor complementarity to act as an agonist at delta and/or mu opioid receptors — triggering the inhibitory G-protein cascade described above.

This receptor-level action is upstream of the events targeted by Argireline (which acts on the SNARE complex, preventing vesicle docking) and distinct from Syn-Ake's postsynaptic mechanism (which blocks the acetylcholine receptor). This mechanistic distinctiveness is what enables genuine additive pharmacology when Leuphasyl is combined with complementary neuropeptides.

Calcium-Channel Blockade and Reduced ACh Release

By inhibiting presynaptic voltage-gated calcium channels via Gi/Go signaling, Leuphasyl reduces the Ca²⁺ transient within the nerve terminal following depolarization. Since neurotransmitter vesicle exocytosis is strictly calcium-dependent, this reduced Ca²⁺ influx results in fewer ACh molecules released into the NMJ synaptic cleft per action potential.

The reduction in synaptic acetylcholine concentration produces a proportional decrease in postsynaptic nAChR occupancy, reducing end-plate potential amplitude and the probability that a given action potential will trigger a full muscle twitch. Over many cycles of facial expression, this dampened neuromuscular transmission may reduce the cumulative mechanical strain on overlying dermis and subcutis.

Catecholamine Inhibition

In addition to ACh at cholinergic synapses, Leuphasyl may inhibit catecholamine (norepinephrine, epinephrine) release at adrenergic nerve terminals in the perivascular and smooth muscle tissue of facial structures, contributing to a broader neuromodulatory profile relevant to vascular tone and local inflammatory mediator release.

---

Research and Clinical Evidence

In Vitro Glutamate Release Inhibition

A key piece of mechanistic validation for Leuphasyl comes from in vitro studies measuring neurotransmitter release inhibition in cultured neuronal preparations. Using a glutamate release assay (glutamate being a proxy for broader calcium-dependent exocytosis):

• •Leuphasyl alone inhibited glutamate release by approximately 11% at tested concentrations
• •Argireline (SNAP-8 formulation) alone inhibited glutamate release by approximately 38%
• •Leuphasyl + Argireline in combination achieved approximately 40% inhibition — exceeding the additive sum and demonstrating synergistic enhancement of neurotransmitter inhibition

This synergy study, conducted by Lipotec S.A. (2005) and subsequently cited in the cosmeceutical literature, became foundational to the formulation philosophy of combining these two peptides in anti-wrinkle products — exploiting mechanistic complementarity at two independent points in the neuromuscular signaling cascade.

In Vivo Clinical Studies

A controlled in vivo study evaluated three concentrations of Leuphasyl formulation (0.5%, 1%, and 2%) applied by 20 volunteers for two months in the eyebrow mimic muscle zone and periorbital region:

• •At 2% concentration, statistically significant wrinkle attenuation was observed versus baseline
• •The study documented wrinkle depth reduction and improved surface smoothness assessed by optical profilometry
• •Importantly, facial expression was preserved throughout the study — consistent with Leuphasyl's mechanism of partial neuromuscular modulation rather than frank paralysis
• •No adverse events or tolerability signals were identified at any concentration tested

Manufacturer data (Lipotec, 2005) further reported that topical application of Leuphasyl at 5% concentration reduced wrinkle severity scores by approximately 11% versus vehicle control over a defined treatment period, confirming dose-dependence of the effect.

Synergy with Argireline: Combined Formulation Evidence

The complementary action of Leuphasyl and Argireline has been documented in a combined product application study in which use of both peptides together produced a 1.5-fold enhanced anti-wrinkle effect compared to Argireline alone — an outcome consistent with the in vitro glutamate inhibition synergy data and with the mechanistic logic of hitting independent nodes in the neuromuscular signaling pathway simultaneously.

Gorouhi and Maibach (Int J Cosmet Sci, 2009; DOI: 10.1111/j.1468-2494.2009.00490.x) reviewed available topical peptide efficacy data and placed enkephalin-pathway peptides including Leuphasyl in the neurotransmitter-inhibitor peptide class — noting the mechanistic distinction from signal peptides and the complementarity with other neuropeptide classes in the botox-like cosmetic category.

---

Mechanistic Comparison: Leuphasyl vs. Related Cosmetic Neuropeptides

---

Peptide Stability and Delivery Considerations

Enzymatic Stability

Leuphasyl's N-terminal acetylation confers meaningful resistance to aminopeptidases and provides a key advantage over native enkephalin in skin application contexts. However, the compound remains susceptible to endopeptidase cleavage by skin-resident enzymes including leupepsin-related and cathepsin families. Formulation strategies to preserve bioactivity include:

• •Encapsulation in lipid nanoparticles or PLGA microspheres
• •pH-buffered cream/serum vehicles (pH 5.0–6.0 matching physiological skin pH)
• •Peptidase inhibitor co-formulation (using natural inhibitors such as zinc ions or specific plant extracts)

Penetration Profile

At approximately 706 Da, Leuphasyl falls above the theoretical 500 Da threshold for passive transdermal diffusion. Enhancing delivery across the stratum corneum is therefore a primary challenge. Studies using fluorescent-tagged analogs have demonstrated accumulation in the viable epidermis and upper dermis using liposomal carriers, with penetration enhancement further improved in formulations containing chemical permeation enhancers (oleic acid, propylene glycol).

---

Position Within Cosmeceutical Neuropeptide Research

Leuphasyl occupies a unique position in the cosmeceutical peptide landscape because it targets an opioid receptor pathway that is well-characterized in central and peripheral nervous system pharmacology but relatively underexplored in the specific context of facial skin biology. As a research tool, it offers:

1. A defined receptor pharmacology (opioid receptor agonist) with abundant reference literature from pain and neuroscience research

2. A manageable molecular size (~706 Da) amenable to formulation strategies targeting skin penetration

3. Documented mechanistic synergy with complementary neuropeptides targeting different points in the neuromuscular cascade

4. Quantifiable in vitro readouts (glutamate release inhibition, calcium flux assays) enabling structure-activity relationship studies on enkephalin-derived sequences

Current research directions for Leuphasyl and related enkephalin analogs include:

• •Receptor subtype selectivity studies: Determining the relative contributions of δ vs. μ opioid receptor agonism to the observed neuromuscular effects
• •Transdermal delivery optimization: Nanoparticle, microneedle, and iontophoresis approaches for improving dermal bioavailability
• •Combination pharmacology: Three-way combinations with Argireline + Syn-Ake for comprehensive neuromuscular cascade inhibition
• •Fibroblast receptor expression: Whether opioid receptors expressed on dermal fibroblasts contribute secondary ECM-modulating effects beyond neuromuscular inhibition

---

Safety Profile

Leuphasyl has been assessed for cosmetic ingredient safety under applicable regulatory frameworks:

• •Sensitization: No sensitization signals identified in Human Repeat Insult Patch Testing (HRIPT) studies across multiple volunteer cohorts
• •Cytotoxicity: MTT and neutral red uptake assays confirm acceptable cell viability at concentrations relevant to cosmetic formulation (typically 0.5–5%)
• •Genotoxicity: Standard Ames test and micronucleus assay results are negative for genotoxic potential
• •Tolerability: In vivo topical application studies at 2% and 5% concentrations confirm absence of erythema, burning, or stinging responses in volunteer populations

> Regulatory Note: Leuphasyl (Pentapeptide-18 / Acetyl Glutamyl Heptapeptide-1) is a cosmetic ingredient, not a pharmaceutical agent, and is not approved for treatment of any medical condition.

---

Summary

Leuphasyl (Pentapeptide-18 / Acetyl Glutamyl Heptapeptide-1) is a mechanistically distinctive cosmeceutical neuropeptide that translates the pharmacology of endogenous enkephalins into a topically applicable, enzymatically stabilized research tool. Its opioid receptor-mediated inhibition of presynaptic calcium-dependent neurotransmitter release positions it at a unique upstream node in the facial NMJ signaling cascade — complementary to the SNARE-targeting mechanism of Argireline and the postsynaptic nAChR antagonism of Syn-Ake. The documented synergy between Leuphasyl and Argireline (1.5-fold enhancement), the in vivo wrinkle attenuation data at 2% topical application, and the well-preserved facial expression outcome collectively define its utility both as a cosmetic active and as a pharmacological research model. For researchers studying opioid receptor biology at the peripheral NMJ, calcium-dependent exocytosis modulation, or cosmetic neuropeptide combinatorics, Leuphasyl offers a well-documented and mechanistically grounded starting point.

---

Disclaimer: This article is for educational and research purposes only. Leuphasyl (Pentapeptide-18) is not approved for therapeutic use. Not for human use.

Key References:

• •Gorouhi F, Maibach HI. Role of topical peptides in preventing or treating aged skin. Int J Cosmet Sci. 2009;31(5):327–345. DOI: 10.1111/j.1468-2494.2009.00490.x
• •Dragomirescu AO, et al. The efficiency and safety of Leuphasyl — A Botox-like peptide. Farmacia. 2014;62(3):596–603.
• •Esposito E, et al. Cosmeceutical peptides in the framework of sustainable wellness economy. Front Chem. 2020;8:572923. DOI: 10.3389/fchem.2020.572923
• •Puig ML, et al. Leuphasyl SNAP-8 combination synergy study. Lipotec S.A. Technical Report. 2005.
• •Lupo MP, Cole AL. Cosmeceutical peptides. Dermatol Ther. 2007;20(5):343–349.